Lupin Limited announced through a regulatory disclosure on February 26, 2026, that CEO Vinita Gupta has been named to the prestigious 2026 CNBC Changemakers list of Women Transforming Business. The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, highlighting the significance of this recognition for the pharmaceutical company.

Regulatory Disclosure and Recognition Details

The company formally notified both the National Stock Exchange of India Limited (NSE: LUPIN) and BSE Limited (Scrip Code: 500257) about this achievement through Company Secretary & Compliance Officer Amit Kumar Gupta. The recognition specifically honors Gupta's contributions to making medicines accessible and affordable for Americans, highlighting her transformative leadership in the global pharmaceutical industry.

Leadership Impact and Business Transformation

The CNBC Changemakers list is an annual recognition program that honors female leaders who are redefining industries, breaking barriers, and driving lasting change across various business sectors. Gupta expressed her honor at being included among such extraordinary leaders, emphasizing that the recognition reflects both her personal journey and the shared dedication of the entire Lupin team who work each day to help transform hope into healing.

Under Gupta's leadership, Lupin has achieved remarkable growth milestones. She built Lupin's U.S. business from the ground up, leading the company to become the third-largest generic medicine supplier to the U.S. and the world's seventh-largest pharmaceutical company by volume.

Recent Strategic Developments

Gupta has made U.S. expansion a core pillar of Lupin's worldwide growth strategy. In 2025, she advanced efforts to strengthen domestic pharmaceutical manufacturing by progressing Lupin's reshoring initiative and announcing plans for a new state-of-the-art inhalation facility in Coral Springs, Florida. The site is anticipated to produce multiple respiratory products, including Albuterol, reinforcing medicine security and improving patient access to critical medicines.

In late 2025, Lupin achieved a significant milestone with FDA approval for its first biosimilar Pegfilgrastim, marking a pivotal step in the company's ongoing commitment to providing high-quality, affordable medicines to U.S. patients. This approval represents an important expansion of Lupin's product portfolio in the biosimilars segment.

Company Profile and Market Position

Lupin Limited operates as a global pharmaceutical leader headquartered in Mumbai, India, specializing in pharmaceutical products including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company maintains a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health.

The company is committed to improving patient health outcomes through its subsidiaries, which include Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. Those recognized in the CNBC Changemakers list will be honored at the CNBC Changemakers Summit on April 16th in New York.

Lupin Limited has achieved a remarkable milestone by securing the No. 1 position globally in the pharmaceutical sector and leading all sectors in India in the S&P Global Corporate Sustainability Assessment 2025. The company announced this achievement on February 26, 2026, highlighting its exceptional performance in environmental, social, and governance (ESG) criteria.

Outstanding Performance in Global ESG Assessment

Lupin attained an impressive score of 91 out of 100 in the comprehensive assessment, establishing itself among the top 1% of companies worldwide. This achievement places the company ahead of both Indian and international peers across all evaluated sectors.

Third Consecutive Yearbook Inclusion

The S&P Global Corporate Sustainability Assessment represents one of the world's most comprehensive ESG benchmarks, evaluating companies on industry-specific economic, environmental, and social criteria. Lupin has earned inclusion in the Sustainability Yearbook 2026 for the third consecutive year, demonstrating consistent excellence in sustainability practices.

The selection criteria for Yearbook inclusion are highly stringent:

• Companies must rank in the top 15% of their industry
• Scores must be within 30% of the industry's top performer
• Of more than 9,200 companies assessed across 59 industries, only 848 earned inclusion

Leadership Commitment to Sustainability

Ramesh Swaminathan, Executive Director, Global CFO and Head of IT and API Plus SBU at Lupin, emphasized the significance of this recognition. He stated that this achievement places Lupin among the topmost global sustainability leaders and reinforces the company's long-term commitment to embedding ESG principles into business strategy.

Strategic ESG Integration

Lupin's recognition reflects its sustained focus on several key areas:

• Responsible business practices across global operations
• Strong governance frameworks
• Environmental stewardship initiatives
• Positive social impact programs
• ESG integration across the entire value chain

The company's performance demonstrates its commitment to creating positive outcomes for patients, communities, and stakeholders worldwide while maintaining leadership in pharmaceutical innovation and manufacturing excellence.

Global Pharmaceutical Leadership

As a global pharmaceutical leader headquartered in Mumbai, India, Lupin distributes products in over 100 markets. The company maintains 15 state-of-the-art manufacturing sites and 7 research centers globally, supported by a dedicated workforce of over 24,000 professionals. This extensive infrastructure enables Lupin to maintain its position as a trusted provider of pharmaceutical products while adhering to the highest sustainability standards.